Dr. Derakhshandeh, PhD Mutation Screening Mutation Screening
Dec 26, 2015
Dr. Derakhshandeh, PhD
Mutation ScreeningMutation Screening
2
Quantitative PCR and Dosage
3
Quantitative PCR and Dosage
used in a number of diagnostic applications eg. SMA trisomy 21 X-linked
Agammaglobulinemia
4
SMA
5
CLASSIFICATIONSMA TYPE I
(Werdnig-Hoffmann)
SMA TYPE II (Classic)
SMA TYPE III (Kugelberg-Welander)
6
SMA TYPE I
Severe form of SMA
Onset : first 6 months
Death : < 2 year
Never raising the head or sitting
7
SMA TYPE I
8
SMA TYPE II
Less severe
Clinical appearing : < 18 months
Able to sit un aid
Death : about 9 years
9
SMA TYPE III
Mildest form of SMA
Onset : > 18 months
Walking without aid
10
GENETIC MAP
Three candidate genes named SMN (Survival Motor Neuron), NAIP (Neuronal Apoptosis Inhibitory Protein) and P44 were identified in this locus
Up to 95% of SMA patients (SMNI-III) are homozygously deleted for two exons (7&8) of both telomeric copy of SMN gene (SMNt)
11
Deletions
Up to 5% of SMA patients have frameshift mutations, gene conversions and point mutation
Exons 5 and 6 of NAIPt gene are deleted in approximately 50% of type I SMA and 18% of types II and III SMA
P44t is lacked or intrrupted in 73%
of SMA type I patients and 7% in types II and III
12
The summery of normal alleles (N) , mutant alleles (M) and deletion types (D) of SMN
13
MOLECULAR DIAGNOSIS & PND
PCR-SSCP or PCR-RFLP of SMN gene enables confirmation of a suspected clinical diagnosis of SMA or prenatal diagnosis
These two techniques based on nucleotide differences of both exon 7 and exon 8 of telomeric and centromeric copy of SMN
14
15
16
17
18
19
Deletion Analysis of SMN gene
• Exones 7 and 8 of SMN gene were amplified and cut by Dra I and Dde I , respectively. (only centromeric copy is cutted)
• Absence of SMNt exone(s) 7 (and 8) confirm diagnosis of SMA
20
21
188 bp
164 bp
188 bp
123 bp
65 bp
Exon 7, DraI
Exon 8, DdeI
22
SMN Deletion AnalysisDerakhshande et al.
(Farhud Genetic Lab/ NRCGEB)
• SMNt Exon 7 is deleted in affected child
23
NAIP Gene Deletion Analysis
• Exones 5 & 6 of NAIP gene were amplified with exon 13 which was the internal control
• Absence of exon 5 and exon 6 ( which only exist within the telomeric functional copy of NAIP) was detected in ~50% of type I SMA and 18% of types II and III SMA
24
NAIP Deletion analysisDerakhshande et al.
(Farhud Genetic Lab/ NRCGEB)
25
26
• The objective of this study was to genetically characterize the childhood onset spinal muscular
atrophy in Iran.
SMN NAIP
Deletion of exon 7 & 8
Deletion of exon 5 & 6
SMA type I (n=70) 70(100%) 61(87%)
SMA type II (n=3) 2(66%) 1(33%)
SMA type III (n=2) 1(50%) 0(0%)
27
• Various deletion haplotypes were constructed by using genotypes of SMN and NAIP genes.
• Haplotype A, which has the deletions of all two involved genes, were deleted in approximately 83% of type I and II SMA but not in type III and was found predominantly in the severe group with an early onset at less than 6 month of age.
• we report Thirty four our experiences for prenatal diagnosis
Haplotypes (%)
A B C
SMA type I (n=70)
87 100 0
SMA type II (n=3)
33 66 33
SMA type III (n=2)
0 50 50
28
• These studies suggested that the frequency of gene deletions of SMN1 and NAIP gene is a few higher than previous reports. It is may be due to high rate of consanguine marriage by Iranian Muslims (96 % in this families). Thus, the conformation of SMA related gene deletion will also be a useful tool for the pre and postnatal diagnostic. In addition to common PCR methods for SMN exon 7 and 8 and NAIP exons 4 and 5, we also conducted multiplex PCR of exon 5, 6 and 13 of the NAIP telomere in one reaction.
29
Quantitative PCR and Dosage
• Products can be measured by image scanning of agarose gels or Polaroid pictures
• Method is not sensitive to template concentration (1.3g to 2.7pg DNA used) but can be affected by template quality so preparation is important.
30
More complex methodSMA
This method allows quantitation of the copy number of SMNT and SMNC genes on chromosome 5q12
31
The homologous gene quantitative polymerase chain reaction(HGQ-PCR)
32
Detection of trisomy 21 by HGQ-PCRLanes 1–16 Serial dilutions for a normal individual and aDown’s syndrome patient used to evaluate
the optimal HGQPCR
33
SequencingSequencing
34
Top and bottom strand differences for a point
mutation
35
Top and bottom strand differences for a heterozygous
base
(Click for full size image)
Figure 2. Top and bottom strand differences for a heterozygous base
36
Sequencing
37
Forensics
38
ForensicsPCR analysis PCR
(polymerase chain reaction)RFLP analysisSTR analysis Short tandem
repeat (STR) technology is a forensic analysis
For example, the likelihood that any two individuals (except identical twins) will have the same 13-loci DNA profile can be as high as 1 in 1 billion or greater.
39
ForensicsMitochondrial DNA Analysis
Mitochondrial DNA analysis (mtDNA) can be used to examine the DNA from samples that cannot be analyzed by RFLP or STR
Nuclear DNA must be extracted from samples for use in RFLP, PCR, and STR
mtDNA analysis uses DNA extracted from another cellular organelle called a mitochondrion
40
ForensicsWhile older biological samples that
lack nucleated cellular material, such as hair, bones, and teeth, cannot be analyzed with STR and RFLP
they can be analyzed with mtDNAIn the investigation of cases that
have gone unsolved for many years, mtDNA is extremely valuable.
41
ForensicsY-Chromosome Analysis
The Y chromosome is passed directly from father to son
so the analysis of genetic markers on the Y chromosome is especially useful for tracing relationships among males
this technique can be very valuable if the laboratory detects complex mixtures (multiple male contributors)
Reverse Dot Blot for Human Mutation
Detection
43
Introduction
• Reverse dot blot (RDB)• or reverse allele specific
oligonucleotide (Reverse ASO)
• hybridization • important method for
genotyping common human mutations
44
Commonly used in:
• a high mutation spectrum• high frequency disorders
such as:– cystic fibrosis– hemoglobin C (HbC)– hemoglobin E (HbE)– hemoglobin S (HbS)– ß-thalassemias
45
Location of mutations in the -globin gene
46
RDB procedure
• exons (or other regions of interest)
• amplified by the polymerase chain reaction (PCR)
• using labeled oligonucleotide primers
• 5' biotin label on PCR primers
47
Amplicons• Amplification products• denatured • hybridized
– with mutation specific DNA probes
• covalently bound to solid membran
48
Incubation• nucleic acids: incubated
with an enzyme conjugated to streptavidin.
• enzyme-conjugated, streptavidin-biotin-nucleic acid complex is then washed
• incubated with– a chromogenic – or luminogenic substrate,
which allows visualization of hybridized spots
49
Materials and Methods
• Total genomic DNA• extracted from peripheral
blood leukocytes • Amniotic fluid cells (AF)• chorionic villi (CVS)
50
A woman having amniocentesis
51
Oligonucleotide probes
• A C6-amino-link phosphoramidite • amino moiety on the 5' end of the
product
52
Oligonucleotides used for reverse dot blot (RDB)
53RDB
54
Reverse dot (RDB) blot hybridization for detection of 10 common β-thalassaemia mutations
55
-thalassemia Patients
56
Screening for causal mutations
• genomic DNA from patient blood samples
• reverse dot blot (RDB) • amplification refractory
mutation system-polymerase chain reaction (ARMSPCR)
• DNA sequencing
57
PCR from genomic DNA
720 bp
58
59
60
Strips
N M
1
2
3
4
5
6
7
8
9
1 2 3 4 5 6 7 8 9 10
61
The Blots
62
Comparison of different factors determining the efficiency of ARMS and reverse hybridization in beta thalassemia diagnosis
ARMS Reverse hybridization
Turnover time several days 6-8 hours
Equipment Expensive (large PCR machine, gel electrophoresis, photodocumentationsystem
Less expensive (small PCR machine, agarose gel, small shaking water bath)
Number of PCR reactions per sample
8-88 1
Documentation Requires documentation process after experiment
Self-documented
Technician time (number of patients: time in days)
1:1 10:1
Starting material Depending on the number of PCR reactions
0.5 μg genomic DNA for just one PCR reaction
Toxic materials Ethidium bromide (carcinogen)
None
63
In the late stages of muscular dystrophy, fat and connective tissue often replace muscle fibers.
64
65
DMD
66
Orthopaedic management of patients with Duchenne's muscular dystrophy
67~95% of deletions can be detected in males using multiplex PCR
L A B C D E F G H L
68
MAPH
•Detection of deletions/duplication mutations in Duchenne Muscular Dystrophy using: Multiplex Amplifiable Probe Hybridisation (MAPH)
69
MAPH• Although ~95% of deletions can be detected
in males using multiplex PCR• other methods must be used to determine
duplications, as well as the carrier status of females
• The most commonly applied methods are quantitative multiplex PCR and quantitative Southern blotting
• The drawback of quantitative multiplex PCR is that often not all mutations are examined
• meaning that small and rare mutations are missed
70
MAPH
• Using high-quality Southern blots it is possible to perform a quantitative analysis and detect duplications
• this technique is time consuming• it is difficult to exactly determine the
duplication • it can be difficult to detect duplications in
females and triplications will be missed
Armour et al (Nucl.Acids Res. 2000)
71
• system for analysing all 79 exons of the DMD gene for deletions and duplications
• MAPH is based on a quantitative PCR of short DNA probes recovered after hybridisation to immobilized genomic DNA
72
• 1 ug of denatured genomic DNA is spotted on a small nylon filter
• hybridized overnight in a solution containing one of the probe mixes
• Following stringent washing the next day the filter is placed in a PCR tube
• and a short PCR reaction is performed• This releases the specifically-bound
probes into the solution• An aliquot of this is transferred to a
second, quantitative PCR reaction